Although it does not appear that CD30 expression has a prognostic role in ENKTL, CD30 is a molecular target for brentuximab vedotin, an anti-CD30 monoclonal antibody, which has led to improved outcomes in patients with refractory classic Hodgkin lymphoma and ALCL [6, 20, 21]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.